20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Biotechnology company Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) posted its financial results Wednesday for the first half and second quarter of 2021 along with a proclamation from the company's president and CEO Ofer Haviv in which he said that this fiscal year is “turning out to be a key strategic year for unlocking value at Evogene and its subsidiaries.”
During the three months ended June 30, the company generated roughly $135 000 in revenue, down by 51.7% year-over-year and missing estimates by $0.08 million. GAAP earnings per share were negative at $0.15, beating projections by $0.02.
In its earnings report, the Rehovot, Israel-based company, revealed having $65.4 million in consolidated cash, cash-related accounts, bank deposits and marketable securities, as of June 30, including $10.6 million, which is appropriated to its subsidiary, Lavie Bio.
In the first six months of 2021, the consolidated net cash usage totaled roughly $11.3 million, or $8.9 million, excluding the Lavie Bio subsidiary.
The consolidated cash usage amounted to $5.7 million for the second quarter, or $4.5 million, excluding the Lavie Bio subsidiary.
According to the company’s management, cash usage for the full year of 2021 will be within the projected range of $20-$22 million.
Other Q2 2021 Financial Highlights
- Research and development expenses were $5 million versus $3.9 million in the corresponding quarter of 2020.
- Business development increased year-over-year to $0.7 million from $0.5 million in the same period of last year.
- General and administrative expenses amounted to $1.8 million compared to $1.1 million in the corresponding quarter of last year.
- Operating loss was $7.4 million, up from $5.2 million in the prior-year period.
- Net loss totaled $6.9 million, which compares to a $4.8 million loss in the second quarter of 2020.
Price Action
Evogene’s shares were trading 1.02% higher at $2.98 per share at market close Tuesday.
Photo: Courtesy of M. B. M. on Unsplash
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!